Metformin 001: The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma

Sponsor

British Columbia Cancer Agency (Other)

Overall Status

Unknown status

CT.gov ID

NCT02978547

Collaborator

Pancreatic Cancer Canada (Other), BC Cancer Foundation (Other)

Enrollment

Location

Arm

Anticipated Duration (Months)

0.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a single arm, non-randomized phase II study of neoadjuvant metformin in resectable PDAC. Twenty patients will be enrolled and treated with metformin 500 mg BD for a minimum of 7 days, until 2 days prior to surgery. Patients will undergo laboratory investigations at baseline, prior to surgery and 4-10 weeks after surgery. Patients eligible for and consented to the optional MRI substudy will undergo diffusion-weighted MRI 1 to 14 days before surgery.

At surgery, resected tumour and normal tissue will be collected and banked. FFPE specimens will be used for sectioning, histological analysis and IHC for Ki67 (cell proliferation marker), pAMPK, ACC targets, p53 and mTOR targets, apoptotic markers (Bax, Bcl-2, caspases 3, 8 and 9). Fresh frozen tumour and matched normal tissue samples will be used for western blot analysis of insulin and IGF receptors, total and activated ERK and Akt, and RNAseq analysis. Pre-metformin biopsy samples will be retrieved for molecular analysis.

Fasting blood samples at baseline and before surgery will be analyzed for glucose and insulin levels. Plasma and whole blood will also be processed and banked for circulating tumour DNA analysis. Urine samples will be sent for metabolomic profiling.

Condition or Disease	Intervention/Treatment	Phase
Resectable Pancreatic Ductal Adenocarcinoma	Drug: Metformin Hydrochloride 500Mg Tablet	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

20 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma

Anticipated Study Start Date :

Jan 1, 2019

Anticipated Primary Completion Date :

Jun 1, 2020

Anticipated Study Completion Date :

Jan 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Metformin All patients will receive metformin 500 mg per oral twice daily with food for at least 7 days, until 2 days prior to surgery. Metformin therapy should be discontinued 2 days before surgery to reduce the risk of lactic acidosis associated with fasting.	Drug: Metformin Hydrochloride 500Mg Tablet In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.

Arm

Intervention/Treatment

Experimental: Metformin

All patients will receive metformin 500 mg per oral twice daily with food for at least 7 days, until 2 days prior to surgery. Metformin therapy should be discontinued 2 days before surgery to reduce the risk of lactic acidosis associated with fasting.

Drug: Metformin Hydrochloride 500Mg Tablet

In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.

Outcome Measures

Primary Outcome Measures

The effect of neoadjuvant metformin treatment on tumour cell proliferation in PDAC tumours [6 months]
Assessment of Ki-67 fraction as assessed by IHC of pre- and post-metformin tumour samples.

Secondary Outcome Measures

R0 resection rates in patients undergoing curative PDAC resection [6 months]
Proportion of patients with R0 resections.
The effect of metformin on glucose and insulin metabolism as assessed by serum marker, fasting GGT (mmol/L) [6 months]
The marker of glucose and insulin metabolism will be reported with pre- and post-metformin values compared.
The effect of metformin on glucose and insulin metabolism as assessed by serum marker, fasting glucose (mmol/L) [6 months]
The marker of glucose and insulin metabolism will be reported with pre- and post-metformin values compared.
The effect of metformin on glucose and insulin metabolism as assessed by serum marker, fasting insulin (mU/L) [6 months]
The marker of glucose and insulin metabolism will be reported with pre- and post-metformin values compared.
The effect of metformin on glucose and insulin metabolism as assessed by serum marker, HOMA index [6 months]
HOMA index is calculated from serum glucose and insulin. The marker of glucose and insulin metabolism will be reported with pre- and post-metformin values compared.
The effect of metformin on glucose and insulin metabolism as assessed by clinical marker, weight (kg) [6 months]
The clinical marker will be reported with pre- and post-metformin values compared.
The effect of metformin on metabolomic profile of pre- and post-metformin samples [6 months]
Serum and urine metabolomic profile. Comparison of metabolite levels in pre-and post-metformin samples.
Transcriptome sequencing (RNAseq) of pre- and post-treatment tumour samples. [6 months]
To investigate the molecular signatures associated with metformin response Comparison of gene expression in pre-metformin biopsy samples and post-metformin resected tumour samples. Expression of altered genes to be validated by IHC in tumour sections.
Plasma ctDNA, measured as percentage of mutant to total DNA fragments in plasma [6 months]
To assess the presence of ctDNA in resectable PDAC, and dynamic changes following treatment with metformin and surgical resection Proportion of patients with detectable plasma ctDNA at baseline. Comparison of values pre- and post-metformin and 4-10 weeks after surgery.
Correlation between imaging and pathologic parameters [6 months]
To explore the correlation between apparent diffusion coefficient (ADC) on MRI and pathologic findings. ADC values will be individually compared to tumour differentiation and Ki-67 fraction on pathologic examination.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age greater than or equal to 18 years on the day of study consent
Pathologic diagnosis of PDAC where 2 pre-treatment core biopsy samples are available for analysis. Patients with suspected PDAC without a pathologic diagnosis must undergo confirmatory biopsy under endoscopic ultrasound guidance.
Resectable disease based on standard imaging criteria
Surgery planned ≥ 2 weeks after study entry
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Adequate hematologic, renal, and hepatic function as measured by the following laboratory assessments conducted within 7 days prior to the initiation of study treatment:
Total bilirubin < 1.5 times the upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 times the ULN
Lipase < 1.5 times the ULN
Serum creatinine < 1.5 times the ULN
Glomerular filtration rate > 30 mL/min/1.73 m2 according to the modified diet in renal disease abbreviated formula
International normalized ratio (INR) or prothrombin time (PT; PT-INR) and partial thromboplastin time (PTT) < 1.5 times the ULN
Platelet count > 100000 /mm3, hemoglobin (> 9 g/dL, absolute neutrophil count > 1500/mm3.
Baseline fasting glucose <13.9 mmol/L
No prior chemotherapy or radiotherapy for PDAC
Serum lactate levels within normal range assessed within 7 days prior to the initiation of study treatment

MRI sub-study:

Signed informed consent for the optional MRI substudy
No contraindications to MRI

Exclusion Criteria:

Presence of locally unresectable disease or distant metastases
Treatment with metformin or any other anti-hyperglycemic agent within the previous 6 months
Known allergy or contraindication to metformin
Not fit for surgery
Planned for, or received, neoadjuvant treatment of any type

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	BC Cancer Agency - Vancouver Cancer Centre	Vancouver	British Columbia	Canada	V5Z 4E6

Sponsors and Collaborators

British Columbia Cancer Agency
Pancreatic Cancer Canada
BC Cancer Foundation

Investigators

Principal Investigator: Daniel J Renouf, MD, British Columbia Cancer Agency

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:

British Columbia Cancer Agency

ClinicalTrials.gov Identifier:

NCT02978547

Other Study ID Numbers:

H16-02566

First Posted:

Dec 1, 2016

Last Update Posted:

Jan 18, 2018

Last Verified:

Jan 1, 2018

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by British Columbia Cancer Agency

Resectable pancreatic ductal adenocarcinoma

PDAC

Metformin

Additional relevant MeSH terms:

Adenocarcinoma

Metformin

Study Results

No Results Posted as of Jan 18, 2018